MHE January 2024

The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).

Lipoprotein(a) is a cardiovascular disease risk factor that does not change with diet and exercise. There are no FDA-approved treatments, but two candidates are in phase 3 trials.

We caught up recently with William Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board. Shrank has held several executive positions with health insurers, most recently Humana. He is now a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California.

U.S. and United Nations health officials have set ambitious 2030 goals for ending HIV and AIDS. It looks like those efforts will fall short unless there is a burst of progress in the next few years.